Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma.
Luttwak E, Nemirovsky D, Devlin SM, Boardman AP, Cassanello G, Corona M, Luan D, Dahi PB, Abia AL, Falchi L, Landego I, Lin RJ, Lue JK, Palomba LM, Park JH, Raj SS, Rejeski K, Rivas Delgado A, Scordo M, Tomas AA, Shah GL, Perales MA, Salles G, Shouval R. Luttwak E, et al. Among authors: nemirovsky d. Hemasphere. 2025 Nov 27;9(11):e70248. doi: 10.1002/hem3.70248. eCollection 2025 Nov. Hemasphere. 2025. PMID: 41321357 Free PMC article.
Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.
Jurgens EM, Mitra S, Herrera K, Nemirovsky D, Bready B, Derkach A, Hosszu K, McAvoy D, Firestone RS, Rajeeve S, Lesokhin AM, Korde N, Tan CR, Hashmi H, Hassoun H, Maclachlan K, Shah UA, Hultcrantz M, Merz M, Maura F, Giralt SA, Shah G, Landau HJ, Scordo M, Santomasso BD, Park J, Leslie C, Usmani SZ, Perica K, Mailankody S. Jurgens EM, et al. Among authors: nemirovsky d. medRxiv [Preprint]. 2025 Oct 30:2025.10.28.25338924. doi: 10.1101/2025.10.28.25338924. medRxiv. 2025. PMID: 41282927 Free PMC article. Preprint.
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma.
Jurgens E, Shekarkhand T, Rueda C, Nemirovsky D, Derkach A, Firestone RS, Miller K, Costa BA, Rajeeve S, Lesokhin AM, Korde N, Tan CR, Hashmi H, Hassoun H, Maclachlan K, Shah UA, Hultcrantz M, Hamadeh I, Giralt SA, Shah GL, Landau HJ, Scordo M, Usmani SZ, Mailankody S, Shahid Z. Jurgens E, et al. Among authors: nemirovsky d. Blood Cancer J. 2025 Nov 1;15(1):189. doi: 10.1038/s41408-025-01393-8. Blood Cancer J. 2025. PMID: 41176584 Free PMC article. No abstract available.
Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.
Anderson DR, Gangaraju R, Sedhom WG, Hamulyák EN, Wang TF, O'Dwyer K, Carney BJ, Muthiah C, Liedtke M, Badar T, Shimony S, Robinson R, Sanfilippo K, Derkach A, Dinner S, Biemond BJ, Nemirovsky D, Goldberg LA, Kapadia AD, Levavi H, Bar-Natan M, Van Hyfte G, Bansal K, Carrier M, Fulcher J, Gerrits AM, Litzow MR, Luger S, Guru Murthy GS, Luskin M, Wolach O, Shomali W, Zwicker JI, Stock W, Leader A. Anderson DR, et al. Among authors: nemirovsky d. Blood Adv. 2026 Feb 10;10(3):593-603. doi: 10.1182/bloodadvances.2025017862. Blood Adv. 2026. PMID: 41170879 Free article.
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Sebastian T, Rajeeve S, Farzana T, Firestone R, Jurgens E, Miller K, Costa BA, Lesokhin A, Tan CR, Shah G, Korde N, Landau H, Scordo M, Hassoun H, Maclachlan K, Shah U, Hultcrantz M, Derkach A, Nemirovsky D, Giralt S, Usmani S, Mailankody S, Hashmi H. Sebastian T, et al. Among authors: nemirovsky d. Blood Cancer J. 2025 Oct 13;15(1):161. doi: 10.1038/s41408-025-01383-w. Blood Cancer J. 2025. PMID: 41083445 Free PMC article. No abstract available.
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH. Valtis YK, et al. Among authors: nemirovsky d. Blood Adv. 2026 Jan 13;10(1):276-288. doi: 10.1182/bloodadvances.2025017526. Blood Adv. 2026. PMID: 41052404 Free PMC article. Clinical Trial.
Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance.
Firestone RS, Simhal AK, McAvoy D, Jurgens EM, Garcés JJ, Nemirovsky D, Derkach A, Maclachlan KH, Hultcrantz M, Mailankody S, Shah UA, Tan CR, Korde N, Hassoun H, Rajeeve S, Hashmi H, Landau HJ, Scordo M, Shah GL, Giralt SA, Diamond BT, Maura F, Hosszu K, Chung DJ, Landgren O, Usmani SZ, Lesokhin AM. Firestone RS, et al. Among authors: nemirovsky d. Clin Cancer Res. 2025 Nov 3;31(21):4446-4456. doi: 10.1158/1078-0432.CCR-25-0572. Clin Cancer Res. 2025. PMID: 40853874 Clinical Trial.
72 results